Heinz-Taheny Kathleen M, Harlan Shannon M, Qi Zhonghua, Heuer Josef G
1 Eli Lilly and Company, Indianapolis, Indiana, USA.
Toxicol Pathol. 2018 Dec;46(8):970-975. doi: 10.1177/0192623318799995. Epub 2018 Sep 13.
Diabetes mellitus (types 1 and 2) is the leading cause of glomerular disease and end-stage renal disease in most developed countries, with estimates that one-third of people living with diabetes will develop diabetic kidney disease (DKD). The current standard of care medications slow but do not arrest progression of kidney disease, and therefore, therapy for DKD is a highly unmet medical need for patients. To discover and test novel and durable new therapies, it is necessary to develop animal models of human DKD, which authentically recapitulate the human disease state and provide translatable efficacy to human patients. Here, we review selected mouse models of human DKD, which demonstrate many of the features of type 2 human DKD.
在大多数发达国家，糖尿病（1型和2型）是肾小球疾病和终末期肾病的主要病因，据估计，三分之一的糖尿病患者会发展为糖尿病肾病（DKD）。目前的标准护理药物虽能减缓但无法阻止肾病进展，因此，DKD的治疗对患者来说是一项尚未得到满足的重大医疗需求。为了发现和测试新型且持久的新疗法，有必要开发人类DKD的动物模型，该模型要能真实再现人类疾病状态，并为人类患者提供可转化的疗效。在此，我们综述了所选的人类DKD小鼠模型，这些模型展现出了许多2型人类DKD的特征。
